The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company
  • Before he departs, Drummond says the company will continue its focus on preventative healthcare, short stay programs, clinical homecare and access to virtual care
  • Medibank Chairman Mike Wilkins has praised Drummond for his tenure saying he’s leaving the company in a stronger position
  • Medibank Private shares are trading 3.36 per cent lower at $2.79

Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company.

Before his departure, Drummond says the company will continue to focus on working to deliver more preventative healthcare, short stay programs, clinical homecare and access to virtual care, such as telehealth.

”Pleasingly, Medibank is on a clear strategic path to grow the private health insurance business at a faster rate and continue the transformation into a broader healthcare company,” Drummond said.

“’I could not have been blessed with a more competent executive leadership team or supportive board,” he continued.

Medibank Chairman Mike Wilkins praised Drummond for his contribution.

“Craig has done a wonderful job in leading and transforming Medibank. He will leave the company in a much stronger position, on a clear strategic path, with a great team. This is the mark of outstanding leadership,” Mike said.

Investors appear to be wary about the management shake-up, with Medibank shares closing  3.36 per cent lower at $2.79.

MPL by the numbers
More From The Market Online
A toilet in an abandoned spot

Immuron progresses development of traveller’s diarrhea drug Travelan

Immuron Ltd has presented a Clinical Study Report to the US Food and Drug Administration following…
Monoclonal antibodies

Telix takes on ‘next-gen’ cancer drug candidates through $372m asset buy

Telix Pharmaceuticals Ltd has entered an asset purchase agreement with antibody engineering company ImaginAb, Inc
AI image of a lung cross section

‘Billion dollar opportunity’: US DoD to fund ‘nuclear-free’ lung scanning pilot for 4DX

4D Medical's radioisotope-free lung scanning tech will form part of a US DoD paid pilot leading…
An owl cocks its head after reading the Mesoblast news

HotCopper users flock to make sense of darling Mesoblast’s ‘proposed financing’

If you’ve been paying attention, you know Mesoblast (ASX:MSB) is currently something of an Australian market darling.